

# Evaluation of the *in vitro* dose-dependent effects of resveratrol on innate immune function in dogs



Rowena Woode, Sandra Bechtel, Yan Zhang, Juliana Amorim, Kaoru Tsuruta, Amy DeClue

Comparative Oncology & Internal Medicine Laboratories, College of Veterinary Medicine, University of Missouri, Columbia, MO

## Introduction


- Resveratrol, a compound found in the skin of grapes, has immunomodulatory activity, stimulating immune function at low concentrations and inhibiting it at high concentrations in human and murine immune cells *in vitro*, as well as counteracting inflammation and improving immune function *in vivo*.
- Resveratrol has potential use as a therapeutic agent in humans and animals, helping to bolster immune function in patients with suppressed immunity, and to suppress immunity in patients with immune dysfunction.
- Companion dogs are ideal to evaluate resveratrol in this capacity since humans and dogs share many of the same environmental influences and develop similar diseases spontaneously.

## Objectives/Hypothesis


- The objective of our study was to evaluate the *in vitro* effects of resveratrol on canine leukocyte phagocytic function, oxidative burst, leukocyte cytokine production capacity, and natural killer cell function.
- We hypothesized that resveratrol would demonstrate a dose-dependent effect on immune cell function in dogs *in vitro* with low concentrations being stimulatory and high concentrations being inhibitory.

## Materials and Methods


- Dogs:** Whole blood samples from 6 healthy, adult, client-owned dogs were used for each assay.
- Cell viability:** Blood was incubated with 120ug/mL (20x concentration) of resveratrol, ethanol or PBS for 4 hours at 37°C, followed by 24 hour incubation with phosphate buffered saline, lipopolysaccharide, lipoteichoic acid and peptidoglycan. Percent live versus dead cells were assessed in each group.
- Incubation:** Blood was incubated with high (6ug/mL), intermediate (3ug/mL) and low (1ug/mL) concentrations of resveratrol and a control solution for 4 hours at 37°C.
- Leukocyte phagocytosis:** Samples were incubated with FITC-labeled *Escherichia coli* or a negative control solution for 10 minutes at 37°C. Phagocytic activity was measured via flow cytometry.
- Leukocyte oxidative burst:** Samples were incubated with unlabeled opsonized *E. coli* bacteria, phorbol 12-myristate 13-acetate (PMA) or a negative control solution for 10 minutes at 37°C. Dihydrorhodamine was added as a fluorogenic substrate. Samples were analyzed via flow cytometry.
- Cytokine Production:** Whole blood treated with resveratrol was incubated with phosphate buffered saline, lipopolysaccharide, lipoteichoic acid and peptidoglycan) for 24hrs at 37°C. Supernatant was collected and cytokine production will be measured using a canine-specific multiplex bead assay.
- Natural Killer (NK) Cell Cytotoxicity:** Whole blood will be treated with resveratrol or control solution, peripheral blood mononuclear cells separated, and then incubated with canine thyroid adenocarcinoma cells (CTAC) for 24 hours at 37°C at NK:CTAC ratios of 1:1, 10:1, 25:1 and 50:1. NK cell cytotoxicity was measured via flow cytometry.



**Figure 1. Gating for DNA positive cells.** Cells staining positive for propidium iodide (PI) DNA stain were isolated based on fluorescence within the first and third decades (R1).



**Figure 2. Gating for DNA positive cells.** Cell populations were separated based on size (FS - forward scatter) and complexity (SS - side scatter), isolating cells into neutrophil (A), monocyte (B) and lymphocyte (C) cell populations. Neutrophils and monocytes were gated in our analysis to evaluate phagocytosis and oxidative burst.



**Figure 3. Gating for FITC positive cells.** Monocyte and neutrophil populations were determined to be either FITC negative (top) or FITC positive (bottom) depending upon whether or not they fluoresced within the first and third decades (R3).


•**Statistical analysis for phagocytosis and respiratory burst:** Shapiro-Wilk test was used to test normality assumptions. One way repeated measures ANOVA and post hoc-Fisher least significant difference method were used to compare data and a p value of <0.05 was considered significant.

### Literature cited

- Johnson, W.D., Morrissey, R.L., Osborne, A.L., Kapetanovic, I., Crowell, J.A., Muzzio, M., Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventative activity. Food Chem. Toxicol.49 (2011) 3319-3327.
- Yong-Hong, F., Wen-Liang, Z., Qing-Li, W., Xiao-Yu, L., Wei-Min, Z., Jian-Ping, Z. Low dose of resveratrol enhanced immune response of mice. Acta Pharmacol Sin 23 (2002) 893-897.
- Svajger, U., Jeras, M. Anti-inflammatory Effects of Resveratrol and Its Potential Use in Therapy of Immune-mediated Diseases. Int Rev Immunol 31 (2012). 202-222.
- Issuree, P., Pushparaj, P., Pervaiz, S., Melendez, A. Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities. The FASEB J vol. 23 (2009). 2412-2424.

## Results

- Cell viability:** Cells incubated with 120ug/mL resveratrol showed average cell viability >85% in all groups, indicating no significant adverse effects on cells.
- Phagocytosis:** There was no statistically significant difference between ethanol control and resveratrol treated groups in percentage of cells performing phagocytosis and the MFI of cells performing phagocytosis.
- Oxidative Burst:** For both *E. coli* and PMA induced oxidative burst, the mean fluorescent intensity was significantly less for cells treated with resveratrol, and this appears to be a concentration dependent response (Figure 4).
  - The MFI for *E. coli* respiratory burst decreased with increasing concentrations of resveratrol.
  - The MFI for PMA respiratory burst decreased with increasing concentrations of resveratrol.
- Leukocyte cytokine production capacity and natural killer cell assays:** These assays are currently being performed.



% E. coli		
Treatment Name	Mean	Std Dev
Control	96.155	2.328
Low R	96.285	3.116
Intermediate R	95.552	2.6
High R	95.868	2.578

% PMA		
Treatment Name	Mean	Std Dev
Control	97.313	2.017
Low R	96.668	3.039
Intermediate R	95.818	3.036
High R	96.517	2.249

MFI E. coli		
Treatment Name	Mean	Std Dev
Control	50.69	11.469
Low R	44.823	10.115
Intermediate R	37.972	7.947
High R	35.73	9.686

PMA MFI		
Treatment Name	Mean	Std Dev
Ethanol	62.062	14.026
Low R	58.078	15.832
Intermediate R	47.43	11.723
High R	41.233	10.504

**Figure 4.** The mean percentage of cells in the cell population engaging in oxidative burst activity upon stimulation with *E. coli* (A) and PMA (C) showed no significant difference between treatment groups. The mean fluorescence intensity (MFI) of cells stimulated with *E. coli* (B) and PMA (D), indicating the degree to which each cell engaged in oxidative burst activity on average, showed statistically significant differences between treatment groups. Star denotes a statistically significant difference compared to control.. Furthermore, this difference shows a dose-dependent effect, with oxidative burst activity decreasing progressively as doses of resveratrol increase..

## Conclusion and Future Directions

This data suggests that resveratrol has immunomodulatory effects in healthy dogs *in vitro*, and that these effects are dose dependent in nature. Further study is warranted *in vitro* to further define these changes, and leukocyte cytokine production assays and natural killer cell assays are underway.

## Funding

Student support provided by a gift from Meril, a Sanofi company.  
Project funding provided by the MU Comparative Oncology Laboratory.